113 related articles for article (PubMed ID: 8137875)
41. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms.
Weizman T; Pick CG; Backer MM; Rigai T; Bloch M; Schreiber S
Eur J Pharmacol; 2003 Oct; 478(2-3):155-9. PubMed ID: 14575800
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
Steinmiller CL; Young AM
Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
[TBL] [Abstract][Full Text] [Related]
43. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
44. Antitussive effects of naltrindole, a selective delta-opioid receptor antagonist, in mice and rats.
Kamei J; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
Eur J Pharmacol; 1993 Nov; 249(2):161-5. PubMed ID: 8287897
[TBL] [Abstract][Full Text] [Related]
45. Antinociceptive properties of oxymorphazole in the mouse.
Wu HE; Sun HS; Darpolar M; Dunn W; Tseng LF
Eur J Pharmacol; 2003 Jul; 473(2-3):143-8. PubMed ID: 12892831
[TBL] [Abstract][Full Text] [Related]
46. Antinociceptive properties of FR140423 mediated through spinal delta-, but not mu- and kappa-, opioid receptors.
Ochi T; Fujii T; Motoyama Y; Goto T
Eur J Pharmacol; 1999 Sep; 380(2-3):73-9. PubMed ID: 10513565
[TBL] [Abstract][Full Text] [Related]
47. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
Suh HH; Tseng LF
J Pharmacol Exp Ther; 1990 Jun; 253(3):981-6. PubMed ID: 2162954
[TBL] [Abstract][Full Text] [Related]
48. In vitro binding affinities of a series of flavonoids for μ-opioid receptors. Antinociceptive effect of the synthetic flavonoid 3,3-dibromoflavanone in mice.
Higgs J; Wasowski C; Loscalzo LM; Marder M
Neuropharmacology; 2013 Sep; 72():9-19. PubMed ID: 23624290
[TBL] [Abstract][Full Text] [Related]
49. The antinociceptive effect of salvinorin A in mice.
John TF; French LG; Erlichman JS
Eur J Pharmacol; 2006 Sep; 545(2-3):129-33. PubMed ID: 16905132
[TBL] [Abstract][Full Text] [Related]
50. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
[TBL] [Abstract][Full Text] [Related]
51. The effect of substance P1-7 amide on nociceptive threshold in diabetic mice.
Ohsawa M; Carlsson A; Asato M; Koizumi T; Nakanishi Y; Fransson R; Sandström A; Hallberg M; Nyberg F; Kamei J
Peptides; 2011 Jan; 32(1):93-8. PubMed ID: 20933559
[TBL] [Abstract][Full Text] [Related]
52. Effects of the delta-opioid receptor antagonist naltrindole on antinociceptive responses to selective delta-agonists in post-weanling rats.
Crook TJ; Kitchen I; Hill RG
Br J Pharmacol; 1992 Oct; 107(2):573-6. PubMed ID: 1330187
[TBL] [Abstract][Full Text] [Related]
53. Effects of diabetes on the morphine-induced Straub tail reaction in mice.
Kamei J; Ohsawa M; Misawa M; Nagase H; Kasuya Y
Neurosci Lett; 1994 Aug; 178(1):66-8. PubMed ID: 7816343
[TBL] [Abstract][Full Text] [Related]
54. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
55. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists.
Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y
Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265
[TBL] [Abstract][Full Text] [Related]
56. Antinociception after intracerebroventricular administration of naltrindole in the mouse.
Stapelfeld A; Hammond DL; Rafferty MF
Eur J Pharmacol; 1992 Apr; 214(2-3):273-6. PubMed ID: 1325358
[TBL] [Abstract][Full Text] [Related]
57. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
58. Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception.
Campbell VC; Taylor RE; Tizabi Y
Alcohol Clin Exp Res; 2007 Aug; 31(8):1435-40. PubMed ID: 17550364
[TBL] [Abstract][Full Text] [Related]
59. Stereoselective mu- and delta-opioid receptor-related antinociception and binding with (+)-thebaine.
Aceto MD; Harris LS; Abood ME; Rice KC
Eur J Pharmacol; 1999 Jan; 365(2-3):143-7. PubMed ID: 9988096
[TBL] [Abstract][Full Text] [Related]
60. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors.
Reche I; Fuentes JA; Ruiz-Gayo M
Eur J Pharmacol; 1996 Dec; 318(1):11-6. PubMed ID: 9007506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
